Search
Fluocinolone acetonide
go.drugbank.com/drugs/DB00591ApprovedInvestigationalVet approved[T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676] … [T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices.
Mixtures: OCIDERM-N, CINOLON-NCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersFludeoxyglucose (18F)
go.drugbank.com/drugs/DB09502ApprovedInvestigationalIt is administered by intravenous injection. … Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with
Categories: Compounds used in a research, industrial, or household settingSynonyms: Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, 18-F FDGPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: POMALYST® 4 MG, POMALYST ® 1 MGLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalBy binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity. … Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma
Categories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell EngagerSynonyms: human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMAmRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigational[L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease. … mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older.
Synonyms: Respiratory syncytial virus pre-fusion glycoprotein F mRNAMaftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors
Categories: Drugs Used in Diabetes, P-glycoprotein inhibitorsPiperonyl butoxide
go.drugbank.com/drugs/DB09350ApprovedVet approvedIt has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. … Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.
Mixtures: Up and up lice killing maximum strength, R & C Shampoo With ConditionerCategories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 InhibitorsAndusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigational[elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant. … Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.